

Resource Summary Report

Generated by [NIF](#) on Sep 16, 2026

NCI-H2170

RRID:CVCL_1535

Type: Cell Line

Proper Citation

RRID:CVCL_1535

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1535

Proper Citation: RRID:CVCL_1535

Description: Cell line NCI-H2170 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung squamous cell carcinoma

Defining Citation: [PMID:8806092](#), [PMID:11030152](#), [PMID:16187286](#), [PMID:18083107](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:24002593](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: EGFR genetic alteration cell panel (ATCC TCP-1027)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H2170

Synonyms: H2170, H-2170, NCIH2170

Cross References: BTO:BTO_0005425, CLO:CLO_0008059, EFO:EFO_0002281, AddexBio:C0016018/4970, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5928, BCRJ:0271, BioGRID_ORCS_Cell_line:529,

BioSample:SAMN03471883, BioSample:SAMN10988373, cancercellines:CVCL_1535, CCRID:1101HUM-PUMC000354, Cell_Model_Passport:SIDM00716, ChEMBL-Cells:ChEMBL3308460, ChEMBL-Targets:ChEMBL1075534, CLS:305276, Cosmic:687815, Cosmic:1802304, Cosmic:1995561, Cosmic:2042870, Cosmic:2060537, Cosmic:2125196, Cosmic:2664252, Cosmic-CLP:687815, DepMap:ACH-000481, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:687815, GEO:GSM62966, GEO:GSM434789, GEO:GSM784214, GEO:GSM794356, GEO:GSM827511, GEO:GSM844639, GEO:GSM887410, GEO:GSM888489, GEO:GSM1670221, IARC_TP53:21558, IGRhCellID:NCIH2170, LiGeA:CCLE_581, LINCS_LDP:LCL-1590, Lonza:949, PharmacDB:NCIH2170_1074_2019, PRIDE:PXD030304, Progenetix:CVCL_1535, PubChem_Cell_line:CVCL_1535, Wikidata:Q54907934

ID: CVCL_1535

Record Creation Time: 20220427T220839+0000

Record Last Update: 20260913T004954+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H2170.

No alerts have been found for NCI-H2170.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Ishida M, et al. (2026) AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers. NPJ precision oncology, 10(1).

Chuikov S, et al. (2026) E2A selectively regulates TGF- β -induced apoptosis in KRAS-mutant non-small cell lung cancer. Molecular oncology, 20(7), 1877.

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. Cancer discovery, 16(1), 81.

Brunner JS, et al. (2026) Aspartate availability drives differential engagement of the malate-aspartate shuttle. Molecular cell, 86(5), 954.

Brady MR, et al. (2026) Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma. Cancer research, 86(5), 1166.

- Nilsson MB, et al. (2026) Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*, 21(6), 103555.
- Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. *Cell reports. Medicine*, 7(4), 102694.
- Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. *Cancer cell*, 43(8), 1530.
- Wang X, et al. (2025) HACD3 promotes malignant progression of NSCLC by suppressing the MKK7/MAPK10 signaling axis. *BMC cancer*, 25(1), 1317.
- Park J, et al. (2025) MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer. *Cell reports*, 44(6), 115722.
- Morel M, et al. (2024) FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling. *Molecular oncology*, 18(3), 762.
- Suvilesh KN, et al. (2024) Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non-Small Cell Lung Cancer Patient-Derived Tumor Organoids. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(17), 3855.
- Savage SR, et al. (2024) Pan-cancer proteogenomics expands the landscape of therapeutic targets. *Cell*, 187(16), 4389.
- Kong C, et al. (2023) MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors. *Molecular cancer therapeutics*, 22(10), 1128.
- Guo L, et al. (2023) Targeting ITGB4/SOX2-driven lung cancer stem cells using proteasome inhibitors. *iScience*, 26(8), 107302.
- Zhang S, et al. (2020) The Negative Cross-Talk between SAG/RBX2/ROC2 and APC/C E3 Ligases in Regulation of Cell Cycle Progression and Drug Resistance. *Cell reports*, 32(10), 108102.
- Liu Y, et al. (2020) Chromosome 3q26 Gain Is an Early Event Driving Coordinated Overexpression of the PRKCI, SOX2, and ECT2 Oncogenes in Lung Squamous Cell Carcinoma. *Cell reports*, 30(3), 771.
- Ge P, et al. (2019) miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer. *BMC cancer*, 19(1), 1203.
- Zhou W, et al. (2018) UBE2M Is a Stress-Inducible Dual E2 for Neddylation and Ubiquitylation that Promotes Targeted Degradation of UBE2F. *Molecular cell*, 70(6), 1008.
- Momcilovic M, et al. (2018) The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma. *Cancer cell*, 33(5), 905.